Prognostic Value of Pre-treatment Albumin/Fibrinogen Ratio in Patients with Diffuse Large B-cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2023.03.021
- Author:
Hong DENG
1
;
Liang ZHANG
1
;
Hong-Yan WANG
1
;
Mei-Jiao HUANG
1
;
Jin WEI
1
;
Xing-Li ZOU
2
Author Information
1. Department of Hematology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
2. Department of Hematology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China. E-mail: zxldylan@nsmc.edu.cn.
- Publication Type:Journal Article
- Keywords:
albumin/fibrinogen ratio;
diffuse large B-cell lymphoma;
prognostic value
- MeSH:
Humans;
Prognosis;
Fibrinogen;
Disease-Free Survival;
Albumins/therapeutic use*;
Hemostatics/therapeutic use*;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Retrospective Studies;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(3):762-768
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the value of pre-treatment albumin/fibrinogen ratio (AFR) on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL).
METHODS:The data of DLBCL patients in the Affiliated Hospital of North Sichuan Medical College from April 2014 to March 2021 were retrieved, and 111 newly diagnosed patients who completed at least 4 cycles of R-CHOP or R-CHOP-like chemotherapy with complete data were included in the study. The clinical, laboratory examination and follow-up data of the patients were collected, and the receiver operating characteristic curve (ROC) was drawn according to patients' AFR before treatment and the survival status at the end of the follow-up, which could be used to preliminarily evaluate the predictive value of AFR for disease progression and patients' survival outcome. Furthermore, the correlation of AFR with the clinical and laboratory characteristics, progression-free survival (PFS) and overall survival (OS) was analyzed, and finally, univariate and multivariate Cox proportional hazard regression models were used to analyze factors affecting PFS and OS of DLBCL patients.
RESULTS:The ROC curve indicated that AFR level had a moderate predictive value for PFS and OS in DLBCL patients, with the area under the curve (AUC) of 0.616 (P =0.039) and 0.666 (P =0.004), respectively, and the optimal cut-off values were both 9.06 for PFS and OS. Compared with high-AFR (≥9.06) group, the low-AFR (<9.06) group had a higher proportion of patients with Lugano III-IV stage ( P <0.001), elevated lactate dehydrogenase (P =0.007) and B symptoms (P =0.038). The interim analysis of response showed that the overall response rate (ORR) in the high-AFR group was 89.7%, which was significantly higher than 62.8% in the low-AFR group (P =0.001). With a median follow-up of 18.5 (3-77) months, the median PFS of the high-AFR group was not reached, which was significantly superior to 17 months of the low-AFR group (P =0.009). Similarly, the median OS of high-AFR group was not reached, either, which was significantly superior to 48 months of the low-AFR group (P < 0.001). In multivariate Cox regression analysis, AFR <9.06 was an independent risk factor both for PFS and OS (HR PFS=2.047, P =0.039; HR OS=4.854, P =0.001).
CONCLUSION:Pre-treatment AFR has a significant value for the prognosis evaluation in newly diagnosed DLBCL patients.
